查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835206

胃癌藥物市場（依治療層級、治療線、通路、給藥途徑、劑型和治療類型分類）－全球預測，2025-2032

Gastric Cancer Drugs Market by Therapeutic Class, Treatment Line, Distribution Channel, Route Of Administration, Dosage Form, Therapy Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃癌藥物市場規模將成長至 66.3 億美元，複合年成長率為 6.32%。

主要市場統計數據
基準年2024年 40.6億美元
預計2025年 43.2億美元
預測年份：2032年 66.3億美元
複合年成長率（%） 6.32%

說明不斷發展的臨床和商業生態系統以及影響胃癌治療的相關人員的策略重點

胃癌是一個複雜的治療領域，生物學、臨床實踐和醫療保健系統政策相互交織，共同影響患者的治療結果。近年來，由於分子生物學的闡明、聯合治療的廣泛應用以及免疫療法和分子標靶藥物的引入，臨床醫生對胃癌的診斷、分期和治療方式迅速演變。這些發展改變了治療途徑，為藥物開發商、支付方和醫療保健提供者創造了獨特的機會和挑戰，使其能夠適應新的療效和安全性特徵以及不斷變化的治療標準。

本摘要總結了影響治療開發和商業化的最重要趨勢。它強調了不斷變化的臨床模式、商業性動態和監管模式，這些趨勢正在重新定義胃腫瘤學的價值獲取。本摘要著重於可操作的洞察而非原始的市場預測，強調了臨床證據、治療可近性和策略定位之間的關聯。其目的是為高階主管、臨床領導者和相關人員提供簡潔而全面的指導，以優先考慮投資、最佳化上市方案，並預測將影響專案可行性和病患可及性的近期曲折點。

精準醫療、免疫腫瘤學的進步以及不斷變化的監管和報銷獎勵如何從根本上重塑胃癌治療模式

胃癌治療領域正在經歷一場變革性的轉變，涵蓋科學創新、監管格局和治療交付模式。在科學方面，精準腫瘤學正在加速融入標準工作流程，分子亞型分析和生物標記主導的患者選擇已常規反映在治療方法決策和試驗設計中。這種個人化治療趨勢提升了伴隨診斷的重要性，並催生了對能夠證明跨明確生物標記層級效用的臨床試驗的需求。同時，免疫腫瘤學正擴展到胃癌領域，包括查核點抑制劑和聯合方案，旨在利用標靶藥物和免疫微環境的協同作用。

法律規範正在適應這些科學進步，簡化基於替代終點的加速核准途徑，以應對高未滿足需求人群的需求，同時強調核准後證據的產生以確認臨床效用。支付方和醫療系統正在製定基於結果的合約機制，並審查真實世界證據以做出覆蓋決策。這些趨勢正在促進協作模式的發展，製造商、醫療保健提供者和診斷開發人員將在證據產生和報銷策略方面展開合作。這些轉變正在重塑整個價值鏈的臨床試驗重點、商業模式和投資策略。

評估近期關稅改革和貿易政策轉變對治療投入和最終產品的策略供應鏈、定價和准入的影響

2025年，影響藥品、零件和相關生技藥品投入的關稅政策為全球供應鏈和商業營運帶來了新的複雜性。關稅調整可能會增加進口活性藥物原料藥、研究耗材和某些成品的到岸成本，從而對製造足跡和籌資策略造成壓力。擁有全球分佈供應鏈的製造商應審查供應商契約，並考慮近岸外包、雙重採購和增加庫存緩衝等方案，以減輕關稅導致的價格波動風險。

累積影響將波及採購、定價和市場進入等各個面向。依賴國際供應商的醫院和醫療系統可能面臨更高的採購成本，這可能導致更嚴格的配方談判和更嚴格的衛生技術評估。製造商將被獎勵最佳化生產佈局，並投資於供應鏈透明度，以支持與付款人進行成本控制討論。同時，公司可能會加快關於基於價值的合約的討論，將價格與產量脫鉤，並將報銷重點放在已證實的臨床結果上。這種轉變也為能夠展示抗關稅採購和敏捷品質保證流程的區域製造夥伴關係和供應商創造了機會。最終，關稅變化將提昇在受影響市場中支持供應鏈敏捷性和持久准入的證據的戰略重要性。

將治療層級、治療路線、分銷管道、給藥途徑、劑型和治療類型與臨床和商業性影響聯繫起來的細分見解

對胃癌治療領域進行細分，有助於明確臨床價值和商業機會的交會點，並揭示不同的產品屬性如何影響產品採用和定位。根據治療層級，生物製藥（包括細胞激素和單株抗體）、化療（包括Fluoropyrimidines、含鉑類藥物和紫杉烷類）、免疫療法（包括癌症疫苗和查核點抑制劑）以及標靶治療（包括 Her2 抑制劑和 Vegf 抑制劑）各自具有獨特的開發途徑和證據要求，並以獨特的方式與診斷、聯合策略和安全監測相互作用。生物製藥製劑亞類之間的區別對於製造複雜性和監管預期至關重要，而化療的既定作用是許多組合方案的基礎，並影響治療方案的決策。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • FDA核准FGFR2b標靶單株抗體，助力胃癌精準治療
  • PD-1/PD-L1 免疫查核點抑制劑在晚期胃癌一線治療通訊協定的應用日益增多
  • 基於ctDNA的液態生物檢體檢測的出現，可用於即時監測胃癌患者的治療反應
  • HER2標靶蛋白酪氨酸激酶抑制劑的擴展為HER2陽性胃腫瘤提供了新的第一線治療
  • 增加對胃癌免疫治療中雙查核點路徑的雙特異性抗體候選藥物的投資
  • 微生物組調節療法因增強胃癌標準化療療效而受到關注
  • 生物製藥公司與診斷公司進行策略合作，開發針對胃癌的伴隨診斷藥物
  • Claudin 18.2 標靶 CAR-T 細胞療法在難治性胃癌病例中顯示出良好的持久療效

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 胃癌藥物市場（依治療層級）

  • 生物製藥
    • 細胞激素
    • 單株抗體
  • 化療
    • Fluoropyrimidines
    • 鉑類藥物
    • 紫杉烷類
  • 免疫療法
    • 癌症疫苗
    • 查核點抑制劑
  • 標靶治療
    • HER2抑制劑
    • VEGF抑制劑

第9章胃癌藥物市場（依治療線）

  • 首選藥物
  • 二線藥物
  • 三線或更高版本

第 10 章胃癌藥物市場按分銷管道

  • 醫院藥房
  • 零售藥局

第11章胃癌藥物市場依給藥途徑

  • 靜脈
  • 口服
  • 皮下

第12章胃癌藥物市場（按劑型）

  • 膠囊
  • 凍乾粉
  • 預填充式注射器
  • 藥片

第13章胃癌藥物市場（依治療類型）

  • 聯合治療
  • 單一療法

第14章胃癌藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章胃癌藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 胃癌藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-437E9896A4F6

The Gastric Cancer Drugs Market is projected to grow by USD 6.63 billion at a CAGR of 6.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.06 billion
Estimated Year [2025] USD 4.32 billion
Forecast Year [2032] USD 6.63 billion
CAGR (%) 6.32%

A concise orientation to the evolving clinical and commercial ecosystem shaping gastric cancer therapeutics and strategic priorities for stakeholders

Gastric cancer remains a complex therapeutic area where biology, clinical practice, and health system policy intersect to shape patient outcomes. Recent years have seen a rapid evolution in how clinicians diagnose, stage, and treat gastric malignancies, driven by improved molecular characterization, broader adoption of multimodal therapy, and the introduction of immune and targeted agents. These developments have altered treatment pathways and created distinct opportunities and challenges for pharmaceutical developers, payers, and providers as they adapt to new efficacy and safety profiles and shifting standards of care.

This summary synthesizes the most relevant trends influencing therapeutic development and commercialization. It highlights changes in clinical paradigms, commercial dynamics, and regulatory patterns that are redefining value capture in gastric oncology. By focusing on actionable insights rather than raw market estimates, the narrative emphasizes the nexus between clinical evidence, treatment access, and strategic positioning. The aim is to equip executives, clinical leaders, and investor stakeholders with a concise but comprehensive orientation to the landscape so they can prioritize investments, refine go-to-market approaches, and anticipate near-term inflection points that will affect program viability and patient access.

How precision medicine, immuno-oncology advances, and evolving regulatory and reimbursement incentives are fundamentally reshaping gastric cancer treatment paradigms

The therapeutic landscape for gastric cancer is experiencing transformative shifts that span scientific innovation, regulatory approaches, and care delivery models. On the scientific front, the integration of precision oncology into standard workflows has accelerated; molecular subtyping and biomarker-driven patient selection are now routinely informing therapeutic decisions and trial design. This movement toward individualized therapy has elevated the importance of companion diagnostics and created demand for trials that demonstrate benefit in well-defined biomarker strata. Concurrently, immuno-oncology has extended into gastric cancer with checkpoint inhibitors and combinatorial regimens that aim to leverage synergy between targeted agents and the immune microenvironment.

Regulatory frameworks are adapting to these scientific advances by streamlining pathways for accelerated approval based on surrogate endpoints in populations with high unmet need, while simultaneously stressing post-approval evidence generation to confirm clinical benefit. Payers and health systems are responding by developing outcome-based contracting mechanisms and by scrutinizing real-world evidence to guide coverage decisions. These dynamics are catalyzing collaborative models where manufacturers, providers, and diagnostic developers align on evidence generation and reimbursement strategies. Together, these shifts are reshaping clinical trial priorities, commercial models, and investment strategies across the value chain.

Assessing the strategic supply chain, pricing, and access implications resulting from recent tariff changes and trade policy shifts affecting therapeutic inputs and finished products

In 2025, tariff policies affecting pharmaceuticals, components, and related biologics inputs introduced a new layer of complexity across global supply chains and commercial operations. Tariff adjustments have the potential to increase landed costs for imported active pharmaceutical ingredients, laboratory consumables, and certain finished formulations, exerting pressure on manufacturing footprints and procurement strategies. Manufacturers with globally dispersed supply chains must reassess supplier contracts and consider options such as nearshoring, dual sourcing, and increased inventory buffering to mitigate exposure to tariff-driven price volatility.

The cumulative impact is felt across procurement, pricing, and market access. Hospitals and health systems that rely on international suppliers may face higher acquisition costs, which can translate into tighter formulary negotiations and more rigorous health technology assessments. Manufacturers are incentivized to optimize manufacturing locality and to invest in supply chain transparency to support cost-containment discussions with payers. In parallel, companies may accelerate conversations about value-based agreements that decouple price from volume and focus reimbursement on demonstrated clinical outcomes. These shifts also create opportunities for regional manufacturing partnerships and for suppliers that can demonstrate tariff-resilient sourcing and rapid quality assurance processes. Ultimately, tariff changes increase the strategic importance of supply chain agility and evidence that supports durable access in affected markets.

Segment specific insights that connect therapeutic class, line of therapy, distribution pathway, administration route, dosage formulation, and therapy composition to clinical and commercial implications

Segmenting the gastric cancer therapeutics landscape clarifies where clinical value and commercial opportunity intersect, and it highlights how different product characteristics influence adoption and positioning. Based on therapeutic class, Biologics including cytokines and monoclonal antibodies, Chemotherapy including fluoropyrimidines, platinum-based agents, and taxanes, Immunotherapy encompassing cancer vaccines and checkpoint inhibitors, and Targeted Therapy with Her2 inhibitors and Vegf inhibitors each have distinct development pathways and evidence requirements, and they interact with diagnostics, combination strategies, and safety monitoring in unique ways. The differentiation between biologic subclasses matters for manufacturing complexity and regulatory expectations, while the established roles of chemotherapy anchor many combination regimens and influence line-of-therapy decisions.

Based on treatment line, differences between first line, second line, and third line or later therapies govern trial design, comparator selection, and the magnitude of unmet need that a new therapy must address. First-line innovations typically require broader safety tolerability and demonstrable improvement in survival or quality of life, whereas later-line agents may gain approval based on smaller, biomarker-enriched populations with clinically meaningful responses. Based on distribution channel, the split between hospital pharmacies and retail pharmacies affects channel economics, patient access points, and the logistics of reimbursement and adherence support. Based on route of administration, the divergence among intravenous, oral, and subcutaneous modalities has implications for site-of-care, patient convenience, adherence, and cost structures, with oral and subcutaneous options often enabling outpatient management and potential shifts away from infusion center utilization.

Based on dosage form, considerations around capsules, lyophilized powder, pre-filled syringe, and tablets extend beyond patient preferences to stability, cold chain logistics, and compounding requirements, which in turn influence procurement and inventory policies. Finally, based on therapy type, the strategic choices between combination therapy and monotherapy drive clinical development complexity, regulatory interactions, and commercial narratives; combination regimens can deliver incremental efficacy but require careful safety management and co-development coordination. Taken together, these segmentation lenses provide a structured framework to prioritize development programs, design differentiated clinical trials, and craft market access strategies that align product attributes with clinical practice and payer expectations.

How regional regulatory diversity, payer frameworks, and healthcare infrastructure dictate differentiated market access and commercialization strategies across major global regions

Regional dynamics play a pivotal role in shaping development priorities, regulatory strategy, and commercialization approaches for gastric cancer therapies. In the Americas, regulatory convergence and established oncology networks support rapid adoption of innovations that demonstrate clear clinical benefit, yet payer scrutiny and value assessment frameworks require robust outcomes evidence and price-value alignment. Health systems in the region are also increasingly receptive to real-world evidence generation and value-based purchasing pilots that can enable earlier patient access while managing budget impact.

In Europe, Middle East & Africa, heterogeneity across regulatory environments and reimbursement pathways necessitates tailored market access strategies and flexible pricing models. While some jurisdictions exhibit strict health technology assessment protocols with cost-effectiveness thresholds, others prioritize access through managed entry agreements or conditional reimbursement linked to post-market evidence. Capacity constraints and variations in diagnostic availability in parts of the region underscore the need for deployment plans that include diagnostic enablement and capacity building to realize the full potential of targeted therapies. In Asia-Pacific, high incidence rates in certain countries, combined with rapidly modernizing clinical infrastructure, create strong demand for therapies that address region-specific molecular epidemiology. Regulatory authorities across Asia are increasingly harmonizing pathways and engaging in expedited review processes for priority medicines, while local manufacturing and licensing partnerships remain central to scaling access and managing commercial risk. Across all regions, alignment between evidence generation, pricing approaches, and delivery infrastructure is essential to convert clinical innovation into broader population impact.

Insights into how research focus, partnership structures, diagnostic integration, and manufacturing strategies differentiate company competitive positioning in gastric cancer therapeutics

Company strategies in gastric cancer therapeutics are diverging along research intensity, portfolio breadth, and partnership models. Some organizations concentrate R&D investment on next-generation targeted agents and biomarker discovery, prioritizing programs that enable narrow indication approvals but high clinical impact. Others pursue combination regimens that pair established chemotherapeutics with immuno-modulatory agents to enhance response durability in broader populations. A growing subset of companies is emphasizing diagnostic co-development and commercial bundling to support precise patient selection and to accelerate reimbursement acceptance.

Commercially, leading firms are experimenting with differentiated pricing approaches, evidence generation partnerships, and lifecycle management strategies that extend utility through new dosage forms or administration routes. Strategic alliances between biotechnology innovators and larger specialty pharmaceutical companies continue to be a dominant model for scaling manufacturing, regulatory submissions, and global commercialization. Additionally, companies with integrated manufacturing capabilities and regional production footprints are better positioned to navigate trade policy shifts and to respond rapidly to formulary decisions. Across the ecosystem, success increasingly depends on demonstrating meaningful patient benefit in real-world settings and on establishing collaborative arrangements with providers and payers to align incentives around value and access.

Practical and high impact strategic actions for developers and commercial leaders to secure clinical adoption, supply chain resilience, and payer alignment in gastric cancer care

Industry leaders seeking to strengthen their position in gastric cancer therapeutics should prioritize integrated strategies that align scientific differentiation with operational resilience and payer engagement. First, invest early in biomarker discovery and companion diagnostic partnerships to maximize the clinical and commercial returns of targeted and immuno-modulatory programs. Diagnostics are critical enablers of precision labeling and help build compelling dossiers for reimbursement discussions. Second, redesign supply chains for greater flexibility by diversifying sourcing, exploring regional manufacturing options, and implementing digital traceability to mitigate tariff and trade risks while improving procurement predictability.

Third, develop evidence generation plans that combine randomized trials with pragmatic real-world studies to address payer concerns about generalizability and long-term outcomes. Purposeful post-approval data collection can unlock managed entry agreements and outcome-based contracts. Fourth, evaluate administration route and dosage form innovation not only through a clinical lens but also as a commercial lever to shift site-of-care, improve adherence, and reduce total cost of care. Fifth, pursue value-focused pricing strategies and commercial models that emphasize demonstrable improvements in survival, quality of life, or healthcare utilization, enabling constructive dialogues with payers and health systems. By implementing these actions in a coordinated manner, organizations can reduce execution risk and accelerate the translation of clinical advances into sustained patient access.

A transparent multi-source methodology combining clinical evidence review, regulatory and payer analysis, and expert validation to derive robust actionable insights

This research synthesized publicly available clinical literature, regulatory decisions, guideline updates, and expert interviews to build a multi-dimensional perspective on gastric cancer therapeutics. The approach combined qualitative thematic analysis of peer-reviewed clinical studies and conference data with structured interviews of oncologists, pharmacoeconomists, and supply chain specialists to capture operational and access considerations. Regulatory pathways and policy developments were reviewed across major jurisdictions to understand approval trends and post-market evidence expectations, and payer literature was examined to identify common value assessment criteria and contracting practices.

Where appropriate, secondary sources were cross-checked against primary documents such as clinical trial protocols, regulatory agency summaries, and professional society guideline statements to ensure factual accuracy. Expert validation workshops were used to refine interpretations and to prioritize strategic implications. The methodology emphasized triangulation across evidence streams and transparent documentation of assumptions to provide stakeholders with a credible and actionable synthesis rather than speculative projections.

A synthesis of key conclusions emphasizing integrated evidence, manufacturing agility, and payer collaboration as the determinants of successful therapeutic adoption in gastric oncology

Gastric cancer therapeutics are at an inflection point where scientific opportunity meets complex operational and policy realities. Innovations in targeted therapies, immuno-oncology, and formulation science promise improved outcomes for defined patient populations, yet achieving broad and sustainable access will require deliberate alignment of evidence generation, supply chain strategy, and value demonstration. Stakeholders that proactively invest in diagnostics, agile manufacturing, and pragmatic evidence generation will be better positioned to convert clinical innovation into durable clinical and commercial impact.

Looking ahead, the most successful programs will be those that integrate clinical differentiation with operational readiness and that engage payers and providers early to co-design access pathways. By focusing on these integrated priorities, organizations can reduce uncertainty, accelerate adoption, and ultimately improve therapeutic options for patients living with gastric cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. FDA approval of FGFR2b-targeted monoclonal antibodies driving precision medicine in gastric cancer therapy
  • 5.2. Rising adoption of PD-1/PD-L1 immune checkpoint inhibitors in first-line treatment protocols for advanced gastric cancer
  • 5.3. Emergence of ctDNA-based liquid biopsy assays enabling real-time monitoring of treatment response in gastric cancer patients
  • 5.4. Expansion of HER2-targeted tyrosine kinase inhibitors offering new first-line options for HER2-positive gastric tumors
  • 5.5. Increased investment in bispecific antibody candidates addressing dual checkpoint pathways in gastric cancer immunotherapy
  • 5.6. Growing focus on microbiome modulation therapies to enhance efficacy of standard chemotherapy regimens in gastric cancer
  • 5.7. Strategic partnerships between biopharma and diagnostic firms to develop companion diagnostics for targeted gastric cancer drugs
  • 5.8. Advancement of CAR-T cell therapies targeting Claudin 18.2 showing promising durable responses in refractory gastric cancer cases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Cancer Drugs Market, by Therapeutic Class

  • 8.1. Biologics
    • 8.1.1. Cytokines
    • 8.1.2. Monoclonal Antibodies
  • 8.2. Chemotherapy
    • 8.2.1. Fluoropyrimidines
    • 8.2.2. Platinum-Based Agents
    • 8.2.3. Taxanes
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Checkpoint Inhibitors
  • 8.4. Targeted Therapy
    • 8.4.1. Her2 Inhibitors
    • 8.4.2. Vegf Inhibitors

9. Gastric Cancer Drugs Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line Or Later

10. Gastric Cancer Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies

11. Gastric Cancer Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Gastric Cancer Drugs Market, by Dosage Form

  • 12.1. Capsules
  • 12.2. Lyophilized Powder
  • 12.3. Pre-Filled Syringe
  • 12.4. Tablets

13. Gastric Cancer Drugs Market, by Therapy Type

  • 13.1. Combination Therapy
  • 13.2. Monotherapy

14. Gastric Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastric Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastric Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. Eli Lilly and Company
    • 17.3.5. AstraZeneca PLC
    • 17.3.6. Daiichi Sankyo Company, Limited
    • 17.3.7. Pfizer Inc.
    • 17.3.8. Johnson & Johnson
    • 17.3.9. Novartis AG
    • 17.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY T